New technologies are now being utilised by legal and IT organizations to automate the analysis, review and production of terabytes of information necessary for e-discovery. From early case assessment to quickly determine what facts are contained in the data, to enterprise legal hold to preserve all relevant information, technology is changing the litigation landscape. Real-world exampleswill be discussed to showhowcases have been won utilising these powerful tools.
Nicole Eagan, CMO, Autonomy ZANTAZ
•How does Hatch Waxman impact the implementation of lifecycle strategies? •Mastering US pharmaceutical patent lifecycle strategies including dosage forms, delivery systems, polymorphs, formulations, controlled release technologies and isomeric purity • Analysing the impact of recent case law including Apotex v Merck (2007), Abbott v Torpharm (2007) and Pfizer v Ranbaxy (2006)
Dr Seth Fidel, Executive Director Legal Affairs and Chief IP Counsel, Neurogen Corporation
•Avoiding the pitfalls of data exclusivity and patent term extensions • Analysing the new EU legislation on biosimilars: Which patents will become important? •Appreciating the impact of competition law in the biosimilars field • Analysis of the impact on your patent strategy of the stringent regulatory regime involved in bringing biosimilars to market Frank Landolt, IP and Legal Counsel, Ablynx Marc Martens, Senior Associate, Bird & Bird